HC Wainwright Has Positive Forecast for BLFS Q2 Earnings

BioLife Solutions, Inc. (NASDAQ:BLFS) – HC Wainwright lifted their Q2 2025 earnings estimates for BioLife Solutions in a report issued on Tuesday, May 13th. HC Wainwright analyst Y. Chen now forecasts that the medical equipment provider will earn ($0.04) per share for the quarter, up from their previous estimate of ($0.06). HC Wainwright currently has a “Buy” rating and a $30.00 target price on the stock. The consensus estimate for BioLife Solutions’ current full-year earnings is ($0.30) per share. HC Wainwright also issued estimates for BioLife Solutions’ Q4 2025 earnings at ($0.04) EPS, Q1 2026 earnings at $0.00 EPS, Q2 2026 earnings at $0.00 EPS, Q3 2026 earnings at $0.03 EPS, Q4 2026 earnings at $0.00 EPS and FY2026 earnings at $0.03 EPS.

BioLife Solutions (NASDAQ:BLFS) last posted its earnings results on Thursday, May 8th. The medical equipment provider reported $0.04 EPS for the quarter, topping analysts’ consensus estimates of ($0.03) by $0.07. BioLife Solutions had a negative return on equity of 6.61% and a negative net margin of 38.98%. The business had revenue of $23.94 million for the quarter, compared to analysts’ expectations of $22.22 million.

Separately, StockNews.com raised BioLife Solutions from a “sell” rating to a “hold” rating in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and six have given a buy rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $31.17.

BioLife Solutions Stock Performance

NASDAQ BLFS opened at $22.05 on Thursday. BioLife Solutions has a 12-month low of $18.70 and a 12-month high of $29.55. The company has a current ratio of 2.78, a quick ratio of 1.78 and a debt-to-equity ratio of 0.03. The business’s 50 day moving average is $23.64 and its two-hundred day moving average is $25.29. The stock has a market capitalization of $1.05 billion, a price-to-earnings ratio of -20.80 and a beta of 2.01.

Institutional Trading of BioLife Solutions

Several large investors have recently added to or reduced their stakes in the company. Steward Partners Investment Advisory LLC purchased a new position in shares of BioLife Solutions during the 4th quarter valued at $26,000. Point72 Asia Singapore Pte. Ltd. bought a new stake in shares of BioLife Solutions during the 4th quarter worth about $31,000. State of Wyoming lifted its holdings in BioLife Solutions by 353.1% in the 1st quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after purchasing an additional 1,490 shares during the last quarter. US Bancorp DE grew its holdings in BioLife Solutions by 243.7% during the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after purchasing an additional 1,528 shares during the last quarter. Finally, 1620 Investment Advisors Inc. grew its holdings in BioLife Solutions by 41.7% during the fourth quarter. 1620 Investment Advisors Inc. now owns 2,295 shares of the medical equipment provider’s stock valued at $60,000 after purchasing an additional 675 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at BioLife Solutions

In other news, CFO Troy Wichterman sold 4,151 shares of the business’s stock in a transaction on Tuesday, March 11th. The stock was sold at an average price of $25.00, for a total transaction of $103,775.00. Following the sale, the chief financial officer now directly owns 116,809 shares of the company’s stock, valued at $2,920,225. The trade was a 3.43% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Aby J. Mathew sold 10,589 shares of the business’s stock in a transaction dated Tuesday, April 1st. The stock was sold at an average price of $22.66, for a total value of $239,946.74. Following the sale, the executive vice president now owns 309,576 shares in the company, valued at approximately $7,014,992.16. The trade was a 3.31% decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 71,696 shares of company stock worth $1,665,094 over the last 90 days. Insiders own 2.20% of the company’s stock.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.